WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, March 08, 2006

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR	
☐	L9	L1 same prodrug	1
☐	L8	L1 with prodrug	1
☐	L7	(glycyl adj prolyl adj isoleucyl adj thiazolidine or glycyl adj isoleucyl adj thiazolidine or alanyl adj isoleucyl adj thiazolidine and prolyl adj isoleucyl adj thiazolidine or pyroglutamyl adj isoleucyl adj thiazolidine or glycyl adj prolyl adj isoleucyl adj pyrrolidine or glycyl adj isoleucyl adj pyrrolidine or alanyl adj isoleucyl adj pyrrolidine or prolyl adj isoleucyl adj pyrrolidine or pyroglutamyl adj isoleucyl adj pyrrolidine) and L1	0
☐	L6	(glycyl adj prolyl adj isoleucyl adj thiazolidine or glycyl adj isoleucyl adj thiazolidine or alanyl adj isoleucyl adj thiazolidine and prolyl adj isoleucyl adj thiazolidine or pyroglutamyl adj isoleucyl adj thiazolidine or glycyl adj prolyl adj isoleucyl adj pyrrolidine or glycyl adj isoleucyl adj pyrrolidine or alanyl adj isoleucyl adj pyrrolidine or prolyl adj isoleucyl adj pyrrolidine or pyroglutamyl adj isoleucyl adj pyrrolidine) and L5	0
☐	L5	(glucose adj tolerance or glucosuria or hyperlipidaemia or acidoses or mellitus or nuropathy or obesity or nephropathy or sequelae) and L3	39
☐	L4	prodrug and L3	29
☐	L3	L1 and (dipeptidyl adj peptidase with inhibitor)	46
☐	L2	L1 (dipeptidyl adj peptidase with inhibitor)	1136
☐	L1	(isoleucyl adj thiazolidine or isoleucyl adj pyrrolidine or allo adj isoleucyl adj thiazolidine or allo adj isoleucyl adj pyrrolidine or valyl adj thiazolidine or valyl adj pyrrolidine)	64

END OF SEARCH HISTORY

```
FILE 'HOME' ENTERED AT 22:37:48 ON 08 MAR 2006

=> b reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42       0.42

FILE 'REGISTRY' ENTERED AT 22:39:00 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    7 MAR 2006  HIGHEST RN 876109-17-0
DICTIONARY FILE UPDATES:   7 MAR 2006  HIGHEST RN 876109-17-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s gpi/sqsp
L1      152187 GPI/SQSP

=> s l1 and sql=3
          2321 SQL=3
L2           0 L1 AND SQL=3




=> file caplus pctfull uspatfull uspat2 biosis scisearch medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    43.33      43.75

FILE 'CAPLUS' ENTERED AT 22:52:32 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 22:52:32 ON 08 MAR 2006
COPYRIGHT (C) 2006 Univentio

FILE 'USPATFULL' ENTERED AT 22:52:32 ON 08 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 22:52:32 ON 08 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 22:52:32 ON 08 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 22:52:32 ON 08 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 22:52:32 ON 08 MAR 2006

=> s isoleucyl thiazolidine or isoleucyl pyrrolidine or allo isoleucyl thiazolidine or allo isoleucyl pyrrolidine or valyl
thiazolidine or valyl pyrrolidine
L3         126 ISOLEUCYL THIAZOLIDINE OR ISOLEUCYL PYRROLIDINE OR ALLO ISOLEUCY
               L THIAZOLIDINE OR ALLO ISOLEUCYL PYRROLIDINE OR VALYL THIAZOLIDI
               NE OR VALYL PYRROLIDINE

=> s l3 and prodrug
L4          65 L3 AND PRODRUG

=> dup remo l4
PROCESSING COMPLETED FOR L4
L5           61 DUP REMO L4 (4 DUPLICATES REMOVED)

=> s l5 and dp iv
L6          37 L5 AND DP IV

=> s l5 and (dp iv or dpiv)
L7          42 L5 AND (DP IV OR DPIV)

=> s l5 and (dp iv or dpiv) and dipeptidyl
L8          42 L5 AND (DP IV OR DPIV) AND DIPEPTIDYL

=> d l8 35-42 bib abs

L8   ANSWER 35 OF 42  USPATFULL on STN
```

AN 2003:195212 USPATFULL
TI Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
IN Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Torsten, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Manhart, Susanne, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Matthias, Wengelsdorf, GERMANY, FEDERAL REPUBLIC OF
Heins, Jochen, Kurort Hartha, GERMANY, FEDERAL REPUBLIC OF
PI US 2003135023 A1 20030717
AI US 2002-186177 A1 20020627 (10)
PRAI US 2001-301158P 20010627 (60)
DT Utility
FS APPLICATION
LREP BROWN, RUDNICK, BERLACK & ISRAELS, LLP., BOX IP, 18TH FLOOR, ONE FINANCIAL CENTER, BOSTON, MA, 02111
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1288
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention involves a compound represented by the general formula (I): ##STR1##

and pharmaceutically acceptable salts thereof,

wherein

A is any amino acid except a D-amino acid;

B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid,

C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine,

D is any amino acid or missing, and

E is any amino acid or missing;

or

wherein

C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and except a D-amino acid,

D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, and

E is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid,

pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and methods of manufacture and use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 36 OF 42 USPATFULL on STN
AN 2003:188406 USPATFULL
TI Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
IN von Hoersten, Stephan, Wedemark, GERMANY, FEDERAL REPUBLIC OF
Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Torsten, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
PI US 2003130199 A1 20030710
AI US 2002-172809 A1 20020613 (10)
PRAI EP 2001-114796 20010627
DE 2001-150203 20011012
DE 2001-154689 20011109
US 2001-301158P 20010627 (60)
US 2002-360909P 20020228 (60)
DT Utility
FS APPLICATION
LREP Mark A. Hofer, Brown Rudnick Berlack Israels, LLP, One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 37 OF 42 USPATFULL on STN
AN 2003:181471 USPATFULL
TI Substituted amino ketone compounds
IN Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Heiser, Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Torsten, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Niestroj, Andre, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
PI US 2003125304 A1 20030703
AI US 2002-287300 A1 20021104 (10)
PRAI DE 2001-DE154689 20011111
US 2001-340182P 20011214 (60)
DT Utility
FS APPLICATION
LREP Brown Rudnick Berlack Israels LLP, 18th Floor, Box IP, One Financial Center, Boston, MA, 02111

CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of the general formula I

B--(CH--R.sup.1).sub.n--C(.dbd.X.sup.2)--D (I)

and pharmaceutically acceptable salts thereof including stereoisomers, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 38 OF 42 USPATFULL on STN
AN 2003:173902 USPATFULL
TI Use of **dipeptidyl** peptidase IV inhibitors
IN Demuth, Hans-Ulrich, Halle, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Torsten, Halle, GERMANY, FEDERAL REPUBLIC OF
Glund, Konrad, Halle, GERMANY, FEDERAL REPUBLIC OF
Heiser, Ulrich, Halle, GERMANY, FEDERAL REPUBLIC OF
Hoersten, Stephan von, Wedemark, GERMANY, FEDERAL REPUBLIC OF
PI US 2003119750 A1 20030626
AI US 2002-126374 A1 20020419 (10)
PRAI EP 2001-114796 20010627
DE 2001-DE150203 20011012
DE 2001-DE154689 20011109
US 2001-301158P 20010627 (60)
US 2002-360909P 20020228 (60)
US 2001-340151P 20011214 (60)
US 2001-340182P 20011214 (60)
DT Utility
FS APPLICATION
LREP BROWN RUDNICK BERLACK ISRAELS LLP, One Financial Center, 18th Floor, BOX IP, Boston, MA, 02111
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2320
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a new use of **DP IV** -inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by **DP IV** or **DP IV**-like enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 39 OF 42 USPATFULL on STN
AN 2003:173888 USPATFULL
TI Methods for improving islet signaling in diabetes mellitus and for its prevention
IN Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Glund, Konrad, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Pospisilik, J. Andrew, West Vancouver, CANADA
Kuehn-Wache, Kerstin, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
PI US 2003119736 A1 20030626
US 6890905 B2 20050510
AI US 2002-216349 A1 20020809 (10)
RLI Continuation-in-part of Ser. No. US 2001-824622, filed on 2 Apr 2001, GRANTED, Pat. No. US 6500804
DT Utility
FS APPLICATION
LREP BROWN, RUDNICK, BERLACK & ISRAELS, LLP., BOX IP, 18TH FLOOR, ONE FINANCIAL CENTER, BOSTON, MA, 02111
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 2337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a **DP IV**-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the β-cells already present that are in need of repair.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 40 OF 42 USPATFULL on STN
AN 2003:141015 USPATFULL
TI Novel antidiabetic agents
IN Evans, David Michael, Southampton, UNITED KINGDOM
PI US 2003096857 A1 20030522
US 6911467 B2 20050628
AI US 2002-129787 A1 20020620 (10)
WO 2000-GB4572 20001130
PRAI GB 1999-28330 19991130
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007

CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1016
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds which are 1-(2'-aminoacyl)-2-cyanopyrrolidine derivatives according to general formula (1) are DP-IV inhibitors for treatment of impaired glucose tolerance or type 2 diabetes; wherein A is selected from groups (2,3 and 4); X is selected from aminoacyl groups corresponding to the natural amino acids, acyl groups R.sup.3CO, groups R.sup.4COOC(R.sup.5)(R.sup.6)OCO, methoxycarbonyl, ethoxycarbonyl and benzyloxycarbonyl; R.sup.1 is selected from H, C.sub.1-C.sub.6 alkyl residues, (CH.sub.2).sub.aNHW.sup.1, (CH.sub.2).sub.bCOW.sup.2, (CH.sub.2).sub.cOW.sup.3, CH(Me)OW.sup.4, (CH.sub.2).sub.d--C.sub.6H.sub.4--W.sup.5 and (CH.sub.2).sub.eSW.sup.6, where a is 2-5, b is 1-4, c is 1-2, d is 1-2, e is 1-3, W.sup.1 is COW.sup.6, CO.sub.2W.sup.6 or SO.sub.2W.sup.6, W.sup.2 is OH, NH.sub.2, OW.sup.6 or NHW.sup.6, W.sup.3 is H or W.sup.6, W.sup.4 is H or W.sup.6, W.sup.5 is H, OH or OMe, and W.sup.6 is C.sub.1-C.sub.6 alkyl, optionally substituted phenyl, optionally substituted heteroaryl or benzyl and R.sup.2 is selected from H and (CH.sub.2).sub.n--C.sub.5H.sub.3N--Y, where n is 2-4 and Y is H, F, Cl, NO.sub.2 or CN, or R.sup.1 and R.sup.2 together are --(CH.sub.2).sub.p-where p is 3 or 4; R.sup.3 is selected from H, C.sub.1-C.sub.6 alkyl and phenyl; R.sup.4 is selected from H, C.sub.1-C.sub.6 alkyl, benzyl and optionally substitued phenyl; R.sup.5 and R.sup.6 are each independently selected from H and C.sub.1-C.sub.6 alkyl or together are --(CH.sub.2).sub.m--, where m is 4-6; R.sup.7 is selected from pyridyl and optionally substituted phenyl; R.sup.8 is selected from H and C.sub.1-C.sub.3 alkyl; and R.sup.9 is selected from H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and phenyl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 41 OF 42 USPATFULL on STN
AN 2003:47782 USPATFULL
TI Compositions for promoting growth
IN Broqua, Pierre, Thoiry, FRANCE
PA Ferring BV, Hoofddorp, NETHERLANDS (non-U.S. corporation)
PI US 6521644 B1 20030218
WO 9819998 19980514
AI US 2002-937031 20020107 (9)
WO 2000-IB393 20000321
PRAI GB 1999-6715 19990323
DT Utility
FS GRANTED
EXNAM Primary Examiner: Henley, III, Raymond
LREP Foley & Lardner
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Inhibitors of dipeptidyl peptidase IV and pharmaceutical compositions comprising these inhibitors are useful in the treatment of short stature due to Growth-Hormone deficiency and for promoting GH-dependent tissue growth or regrowth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 42 OF 42 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2001:2379 BIOSIS
DN PREV200100002379
TI Prodrugs of DP IV-inhibitors strongly improve incretin-mediated glucose tolerance.
AU Demuth, Hans-Ulrich [Reprint author]; Hoffmann, Torsten; Freyse, Ernst-Joachim; Berg, Sabine; Heinke, Peter; McIntosh, Christopher H. S.; Pederson, Raymond A.
CS Probiodrug Research GmbH, Halle/Saale, Germany
SO Diabetes Research and Clinical Practice, (September, 2000) Vol. 50, No. Suppl. 1, pp. S386. print.
Meeting Info.: 17th International Diabetes Federation Congress on Diabetes Research and Clinical Practice. Mexico-City, Mexico. November 05-10, 2000. International Diabetes Federation.
CODEN: DRCPE9. ISSN: 0168-8227.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 21 Dec 2000
Last Updated on STN: 21 Dec 2000